Biologics Discovery CRO:
End-to-End, Under One Roof
Mosaic Biosciences provides integrated biologics discovery services spanning antibody discovery, protein engineering, cell-based assays, protein analytics, and pharmacology, advancing programs from concept to candidate selection with scientific continuity.
216+
Discovery programs completed to date.
80%
Of scientific staff hold advanced degrees (PhD/MS).
504+
Peer-reviewed publications and patents authored by Mosaic scientists.
50+
Experienced scientists and program leaders.
100%
Research conducted in the USA.
Integrated Biologics Discovery
Every Stage, One Partner
Antibody Discovery & Optimization
Integrated in vitro and in vivo discovery workflows using high-throughput screening, molecular engineering, and functional characterization to identify and optimize therapeutic antibody candidates.
Protein Design & Engineering
Computational and experimental protein engineering enabling rational design, optimization, and developability assessment of therapeutic proteins across diverse modalities.
Cell-Based Assays
Fit-for-purpose cell-based assay development supporting functional characterization, mechanism-of-action studies, and potency evaluation of biologic therapeutics.
Protein Sciences & Analytics
Comprehensive protein characterization and developability assessment — biophysical analysis, stability testing, and advanced analytical workflows to evaluate structure, function, and manufacturability.
Pharmacology
Translational pharmacology studies evaluating efficacy, mechanism of action, and in vivo activity to support candidate validation and advancement toward clinical development.
Services can be engaged independently or combined into a fully integrated discovery program, whatever fits your stage, team, and goals.
Programs Across Diverse Modalities and Targets
Mosaic has supported discovery and engineering programs spanning antibodies, multispecifics, engineered proteins, and complex biologic modalities across oncology, immunology, ophthalmology, and rare disease targets. Teams can engage individual services or deploy Mosaic’s full discovery platform for seamless progression from early discovery through preclinical candidate selection.
Experts From the World’s Top Organizations
Eric Furfine, PhD
Chief Scientific Officer
Led IPO-financed Phase 3 programs at Eleven Biotherapeutics. Built the Adnectin platform (acquired by BMS). Former VP at Regeneron contributing to Eylea development.
Tracy Mullen
Chief Strategy Officer
Former SVP Biopharma at Twist Bioscience (post-Abveris acquisition). Former CEO of Abveris. Antibody discovery leadership experience at Biogen and Adimab platform implementation.
Alexei Kazantsev, PhD
Sr. Director Protein Design and Engineering
Structural and chemical biology expert. Leads protein engineering and PK optimization at Mosaic. Prior research in RNA and protein structural biology using X-ray crystallography and SAXS.
Scott Glaser PhD
SVP, Biologics Discovery
30+ years in biologic drug discovery. Former Director of Antibody Therapeutics at Novartis (GNF) and senior leadership at Pfizer and Biogen. Contributor to 50+ discovery programs and co-inventor on 23 US patents.
Looking for a Biologics CRO Partner?
Tell us about your program, your target, and your goals. Our scientific team responds within one business day.
Start a conversation with our scientific team about your discovery program today